drug
RAP-219
Phase 2updated 6mo agoby $RAPP Rapport Therapeutics, Inc.
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying RAP-219
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- phase2Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
- phase2Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
- phase2A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
News(4)
- Rapport’s epilepsy drug finds surprising success in bipolar trialDespite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market opportunity.biopharma_dive · 27d ago
- Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trialRapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential pipeline-in-a-product—this time showing improvement in symptoms of bipol…biospace · 27d ago
- Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambitionRapport Therapeutics’ phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multiindication blockbuster. However, the effect size fell short o…fiercebiotech · 28d ago
- Rapport ‘fully prepared’ to launch seizure drug solo, CEO saysIn a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.biopharma_dive · 5mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that